-
Mashup Score: 14Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies - 2 year(s) ago
In patients with resected colorectal cancer, minimal or molecular residual disease (MRD) assays are now available either commercially or through expanded access programs/clinical trials.1 They can be broadly divided into two types of liquid biopsies.2 First came the tumor-informed circulating tumor DNA (ctDNA)–based platforms in 2019 in the United States (Signatera).3,4 Recently, in 2021,…
Source: JCO Precision OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5Annual Meeting in Real Practice - 2 year(s) ago
Doing What’s Best for Your Patients: Putting the Latest Findings from the 2022 ASCO Annual Meeting Into Practice in LMIC Settings To guide physicians in low- and middle-income countries (LMICs) in putting the latest science and evidence from the 2022 ASCO Annual Meeting into practice, ASCO is offering two free webinars in the weeks following the meeting. Each webinar will be 30 minutes long, with…
Source: ASCOCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo i…
Source: evidence.nejm.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Improvement in Cancer Mortality Lagging in Rural Areas Compared With Urban Cities in the United States - 2 year(s) ago
Cancer mortality has been decreasing in the United States over the last 20 years, but improvements in mortality rates have been slower in rural areas, according to results of a study that will be presented during the 2022 ASCO Annual Meeting (Abstract 6553).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Clinical Trials Updates in the Treatment of Older Adults With Gastrointestinal Malignancies - The ASCO Post - 2 year(s) ago
The theme of the 2022 ASCO Gastrointestinal Cancers Symposium was “Accelerating Access to Precision Care Through Innovation.” Several studies presented at this meeting focused on older patients, who represent the majority of patients with gastrointestinal malignancies. Data reviewed at the meeting and featured here…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The emerging role of ctDNA in cancer diagnostics - 2 year(s) ago
Justin Mencel, MBBS, The Royal Marsden NHS Foundation Trust, London, UK, describes where circulating tumor DNA (ctDNA) is heading in…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
David Bing Zhen, MD, University of Washington Medicine, Seattle, WA, talks on improving responses to immunotherapy for patients with pancreatic…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Adding the immunotherapy to chemotherapy in the frontline setting may improve overall survival for patients with advanced biliary tract cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Naureen Starling, BSc, FRCP, MD, The Royal Marsden NHS Foundation Trust, London, UK discusses the future possibilities for circulating tumor…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Combining immunotherapy and chemotherapy in rectal cancer - 2 year(s) ago
Ali Shamseddine, MD, American University of Beirut, Beirut, Lebanon, explains how there are many Phase II trials investigating the use…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
RT @pashtoonkasi: #GI22 @ASCO🗞 Adding to the #ctDNA📂 Hot off the press 🆕@JCOPO_ASCO #OpenAcess 📝 https://t.co/YxzjLLILon Tumor-Informed…